Omega-3 fatty acids may inhibit prostate cancer cell growth
the ONA take:
In contradiction to a 2013 study, researchers have found a mechanism in omega-3 fatty acids may inhibit the growth and spread of prostate cancer cells. The new study was published in the Journal of Pharmacology and Experimental Therapeutics.
Kathryn Meier, PhD, and two students at Washington State University looked at prostate cell cultures and found that fatty acids are able to bind to FFA4, the “free fatty acid receptor 4”, which inhibits growth factors and suppresses the spread of cancer cells.
“This kind of knowledge could lead us to better treat or prevent cancer because now we know how it works,” Dr. Meier said.
This study contrasts with a 2013 study published in the Journal of the National Cancer Institute which found that men with higher levels of omega-3 fatty acids in their blood had a greater risk of developing prostate cancer.
However, it is still unclear if the effect can be obtained through dietary supplements, and that the drug needs to be in a cancer cell constantly in order to take effect.
A mechanism in omega-3 fatty acids may inhibit the growth and spread of prostate cancer cells.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|